These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 34394131)
1. GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models. Hess NJ; Brown ME; Capitini CM Front Immunol; 2021; 12():723544. PubMed ID: 34394131 [TBL] [Abstract][Full Text] [Related]
2. Early myeloid-derived suppressor cells (HLA-DR Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
4. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. Shimoni A; Nagler A Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195 [TBL] [Abstract][Full Text] [Related]
5. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Chang YJ; Zhao XY; Huang XJ Front Immunol; 2018; 9():3041. PubMed ID: 30619371 [TBL] [Abstract][Full Text] [Related]
6. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173 [TBL] [Abstract][Full Text] [Related]
7. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation. Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280 [TBL] [Abstract][Full Text] [Related]
8. Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia. Merli P; Algeri M; Galaverna F; Milano GM; Bertaina V; Biagini S; Girolami E; Palumbo G; Sinibaldi M; Becilli M; Leone G; Boccieri E; Grapulin L; Gaspari S; Airoldi I; Strocchio L; Pagliara D; Locatelli F Front Immunol; 2020; 11():699. PubMed ID: 32477328 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease. Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration. Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H Front Immunol; 2021; 12():785774. PubMed ID: 34987512 [TBL] [Abstract][Full Text] [Related]
11. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768 [TBL] [Abstract][Full Text] [Related]
12. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664 [TBL] [Abstract][Full Text] [Related]
13. Increased splenic human CD4 Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002 [TBL] [Abstract][Full Text] [Related]
14. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
18. Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Törlén J; Gaballa A; Remberger M; Mörk LM; Sundberg B; Mattsson J; Uhlin M Biol Blood Marrow Transplant; 2019 Jun; 25(6):1260-1268. PubMed ID: 30710687 [TBL] [Abstract][Full Text] [Related]
19. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival. Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V Front Immunol; 2019; 10():3027. PubMed ID: 31998310 [TBL] [Abstract][Full Text] [Related]